Moleculin Biotech Inc. has announced that it received a delisting determination letter from the Nasdaq Stock Market after failing to regain compliance with the minimum $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company did not meet alternative listing standards related to market value or net income. Moleculin intends to appeal the decision to a hearing panel, which will allow its shares to continue trading on the Nasdaq Capital Market under the symbol "MBRX" while the appeal is pending. If the appeal is unsuccessful, the company's securities are at risk of being delisted as early as December 2, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-036006), on November 21, 2025, and is solely responsible for the information contained therein.